cis-Davanone is the signature furanoid sesquiterpene ketone of davana oil and one of the archive's clearest chemotype-defining constituents. Public evidence strongly supports its identity, stereochemical characterization, and dominant occurrence in Artemisia pallens oils, while early pharmacology papers add direct anti-inflammatory cell data and a small animal-model neuroprotection signal. Those results are still preclinical, so AromaForge should describe cis-davanone as a high-relevance davana marker with emerging mechanism research rather than a clinically validated active.
Chemical identity and composition
PubChem lists davanone as C15H24O2, while NIST and The Good Scents specifically connect cis-davanone to the stereochemical 5-hepten-3-one furanoid ketone entry commonly used in fragrance chemistry. Public sources also show registry variation between generic davanone and cis-specific davanone records, so aliasing matters here. In the archive, cis-davanone is the major constituent of davana oil at 45.8% in the base davana profile, and newer literature reports around 53.0% in a characterized davana oil sample.
Aroma and practical use
- Use the recorded fruity, sweet, herbal, wine-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2021 Chemistry and Biodiversity paper reported cis-davanone at 53.0% in davana oil and found that both the whole oil and isolated cis-davanone inhibited lipopolysaccharide-induced TNF-alpha and IL-6 in primary macrophages.
This is the strongest directly attributable constituent-level pharmacology source located in this pass because it links identity, isolation, and a measured cytokine-inhibition result for cis-davanone itself.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2022 Biochemical and Biophysical Research Communications paper tested cis-davanone, bicyclogermacrene, and cis-hydroxy-davanone in a Caenorhabditis elegans Parkinsonism model.
The paper supports early neuroprotective research interest in isolated davana sesquiterpenoids, but the abstract highlights bicyclogermacrene as the compound with the strongest reported effect.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 1999 Journal of Agricultural and Food Chemistry paper reported davanone as the major constituent of davana oil and found that its proportion decreases as the crop advances from full flower-head emergence to seed-set initiation.
This supports cis-davanone as a quality and harvest-timing marker even though the paper does not provide a direct human-use or isolated pharmacology result.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2007 supercritical-fluid chromatography paper reported near-100% optically pure enriched davanone from natural davana oil after isolation and stereochemical characterization.
This source is valuable for constituent identity and stereochemical handling because it specifically addresses isolation integrity and characterization of davanone from natural davana oil.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot assessed
Not assessed in the available record.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot assessed
Not assessed in the available record.
Penetration enhancementNot assessed
Not assessed in the available record.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The Good Scents davanone page reviewed in this pass lists no determined oral, dermal, or inhalation toxicity values and shows a 'not for fragrance use' style recommendation rather than a verified finished-product safety limit.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No constituent-specific IFRA category limit, human tolerability study, or phototoxicity warning for isolated cis-davanone was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Because direct efficacy evidence remains preclinical, archive summaries should avoid translating cis-davanone cytokine or neuro-model findings into medical claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
reduction_of_lps_induced_pro_inflammatory_cytokines
In primary macrophages, cis-davanone reduced lipopolysaccharide-induced TNF-alpha and IL-6 output without reported cytotoxicity at effective concentrations.
This experimental finding does not establish benefit, dose or safety in people using this blend.
possible_neuroprotective_redox_related_activity_in_worm_model
A Caenorhabditis elegans Parkinsonism study included cis-davanone among tested davana sesquiterpenoids, supporting exploratory neuro-model relevance, although the paper's mechanistic emphasis centered on a different isolate.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical study specific to isolated cis-davanone was verified in this pass.
- Public safety sources reviewed here do not establish a constituent-specific dermal maximum or robust toxicology profile for isolated cis-davanone.
- The strongest pharmacology evidence is still limited to cell and small-model systems rather than human translation.
- Web search (2026-07-13) covering davanone dermal limit / IFRA / sensitizing / phototoxic returned only generic IFRA/RIFM framework pages, no davanone-specific standard or assessment. The previously recorded dermal_limit_pct of 2 had no locatable citation and has been corrected to null rather than left as an unsupported figure.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.